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We are in the midst of a rapidly evolving era of technology-assisted medicine. The field of telemedicine provides the opportunity for highly
individualized medical management in a way that has never been possible before. Evolving medical technologies using cardiac implantable
devices (CIEDs) with capabilities for remote monitoring permit evaluation of multiple parameters of cardiovascular physiology and risk,
including cardiac rhythm, device function, blood pressure values, the presence of myocardial ischaemia, and the degree of compensation
of congestive heart failure. Cardiac risk, device status, and response to therapies can now be assessed with these electronic systems of detec-
tion and reporting. This document reflects the extensive experience from investigators and innovators around the world who are shaping the
evolution of this rapidly expanding field, focusing in particular on implantable pacemakers (IPGs), implantable cardioverter-defibrillators
(ICDs), devices for cardiac resynchronization therapy (CRT) (both, with and without defibrillation properties), loop recorders, and haemo-
dynamic monitoring devices. This document covers the basic methodologies, guidelines for their use, experience with existing applications,
and the legal and reimbursement aspects associated with their use. To adequately cover this important emerging topic, the International
Society for Holter and Noninvasive Electrocardiology (ISHNE) and the European Heart Rhythm Association (EHRA) combined their exper-
tise in this field. We hope that the development of this field can contribute to improve care of our cardiovascular patients.
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Introduction
Cardiovascular implantable electronic devices (CIEDs)1,2 have
expanded in number and complexity since their introduction in
1958. On the basis of Eucomed data, 395 000 implantable pace-
makers (IPGs) and 62 000 implantable cardioverter-defibrillators
(ICDs) were implanted in European countries included in the
Eucomed survey during 2009.3 Since some countries are missing in
the survey, average overall implantation rates of 947/million for
IPGs, 149/million for ICDs, and 26/million for cardiac resynchroniza-
tion therapy (CRT)-Ps and 85/million CRT-Ds are estimated which
was applied to the total population of ‘Europe 27’, i.e. 497 659.81
million. This would lead to total implants in 2009 in ‘Europe 27’ of
471 284 IPGs and 74 151 ICDs3 (Figure 1A–C).
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Figure 1 (A–C) Implanted cardiac devices per million inhabitants in Europe. Reproduced with permission from Eucomed.3




















This expanding population of patients with implantable cardiac
devices requires special care. The devices require regular technical
checks and adaptation of their function to the needs of individual
patients. Furthermore, implanted devices provide a new source
for continuous monitoring of biosignals that may contain relevant
medical information.
The logistics of monitoring these devices have already placed a sub-
stantial and increasing burden on the cardiovascular community.4 In
addition, since these are implantable devices, there is an ongoing op-
portunity and responsibility to manage both the patient and the device.
On the other hand, telecardiology is a growing entity with more
and more applications in arrhythmias and device evaluation. During
the last decade, it has evolved rapidly from an experimental diag-
nostic method to its current status; however, there is a lack of
information and agreement regarding the application, utility, and
reimbursement of telemonitoring through devices.
Cardiac patients represent the largest segment of patients being
monitored by wireless telemetry. Wireless medical telemetry pro-
vides access to measurement and recording of physiological par-
ameters and other patient-related information via transmitted
electromagnetic signals.
The data downloaded from the device by the transmitter is then
sent to the hospital or manufacturer centre, either manually or
automatically, using either the landline phone or a mobile telecom-
munications [usually global system for mobile communications
(GSM)] network. The information is received, analysed, and
made available to the treating physician. Although it is not an emer-
gency system, it helps to generate a fast response.5
Many current CIEDs are able to automatically execute the tests
that are performed manually at the outpatient clinic, such as
battery status, lead impedances, or sensing and capture thresholds.
Data acquired automatically on a pre-defined periodic basis by the
device can then be sent from the patient’s home to the physician
using the transmitter, thus, avoiding an unnecessary in-clinic visit.
Rapid advances in technology and wider availability of patient-
friendly equipment give the patient the opportunity to get involved
in his own care with unscheduled transmission of any pre-defined
alerts to the physician, and on the other hand help the providers of
care to identify early signs of worsening heart failure and its preci-
pitating factors or of arrhythmias such as atrial fibrillation (AF).
Therefore, remote monitoring (RM) has the potential to offer
improved patient safety and quality of care.6
The purpose of this position paper is to delineate the current
status and potential future direction to make effective and efficient
use of telemonitoring in implanted devices and to focus on the
follow-up of patients with CIEDs by providing daily information
on the device and the performance of the patient to their phys-
icians using wireless communication. This document is intended
to describe the medical aspects of these activities, including defi-
nitions, utility, benefits, legal aspects, and reimbursement for tele-
medicine in CIEDs. The implementation details in telemonitoring
and follow-up will vary in differing geographic locations with
diverse medical and governmental structures, but it is the intent
to provide suggestions for universally applicable and clinically
appropriate monitoring of CIEDs.
Definitions
According to the expert consensus document of Heart Rhythm
Society (HRS)/European Heart Rhythm Association (EHRA) on
CIEDs monitoring,4 the availability of RM and, in the future,
remote programming of CIEDs will require a change in CIEDs’
follow-up paradigms and protocols. Remote monitoring technol-
ogy may reduce face-to-face clinic visits and will provide essential
and timely information, when visits are triggered by a clinical
event. In addition, RM and the resulting collection of device com-
ponent long-term reliability data, may aid in the assessment of
CIEDs’ system performance. The system may then act as a
Figure 1 Continued




















warning mechanism for the early discovery of potential issues and
clinical conditions that may lead to an increased frequency of in
person or remote surveillance.
Our intention is to define the different nomenclature that has
been used so far in traditional device follow-up and in the newly
developed RM and follow-up, in an effort to standardize the
terms normally utilized in the description of the functionality of
these devices and their monitoring ability (Table 1).
Equipment
Devices currently amenable of remote monitoring
The current CIEDs being interrogated remotely include:7 pace-
makers (PMs), ICDs, CRTs, implantable loop recorders (ILRs),
and implantable haemodynamic monitors.
Device interrogation
It uses telemetry to retrieve information on the CIED-
programmed parameters and data stored in the CIED memory.
These data may be retrieved and stored directly in a CIED pro-
grammer, on a dedicated personal computer or retrieved and
then stored remotely on a server to be viewed on an internet
website.
Device programming
Bidirectional telemetry using encoded and encrypted radiofre-
quency signals from a programmer, allows non-invasive, reversible
changes in some of the operating parameters of the CIED that
enables the operator to select CIED settings to assess and opti-
mize the system performance and longevity and to tailor these par-
ameters to the individual patient’s condition. Because of safety
considerations, device programming can only be done by the use
of a specific programmer in the setting of a face-to-face evaluation.
Programmer
It is a device designed to receive and transmit information via tele-
metry from a family of CIEDs. Programmers are manufacturer
specific and will display and print the information to the operator
and temporarily or permanently program the behaviour of the
CIED. Traditionally, programmers communicated with CIEDs via
a ‘wand’, attached by a wire to the programmer and positioned
on the body’s surface over the CIED implantation site to receive
the telemetry signal. However, modern devices can be interro-
gated and programmed ‘remotely’, i.e. without the use of a
wand. The distance for radiofrequency communication has
increased from several cm (2–5 in) to several meters
(10–20 ft).8 The ability to remotely communicate with a station
has opened the possibility of ‘in-home monitoring’ as it will be
defined later. This remote telemetry is device specific but
employs either the Industrial, Scientific, and Medical band from
902 to 928 MHz or a subsection of the Medical Implant and
Communications band from 402 to 405 MHz.
Home monitor/communicator
This is a remote telemetry device able to communicate with the
CIED automatically in real time or at scheduled intervals, and that
transmits the encrypted data over long distances utilizing telephone
lines or cellular phone technology. The data are then entered and
stored in dedicated servers that act as data repositories that commu-
nicate actively or passively with the caregivers of the patient.
Remote monitoring systems
Remote monitoring of PMs trans-telephonically (TTM) was intro-
duced in 1971 and remained until recently the main technology
to remotely follow the performance of PMs. It is mostly aimed
at ascertaining the integrity of the system especially with regard
to battery performance and longevity, appropriate capture, and
sensing.
With the advent of remote wireless communication from the
CIED to a home monitor/communicator and in turn the ability
to transmit and store all data that the CIED is capable of collecting,
manufacture-specific remote monitor systems proliferated, and
become the new standard for remote follow-up (Medtronic Care-
Link, Boston Scientific Latitude, Biotronik Home Monitoring, Sorin
Smart View and St Jude Merlin.net).9 –13 A brief display of their
properties is included in Table 2.6
Remote follow-up and monitoring
clinical scenarios
The circumstances in which this occurs and the protocols to
obtain the information and disseminate it to the caregivers vary
by manufacturer and the capabilities of each RM system (refer to
Table 1). The most common clinical scenarios are defined below.
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Table 1 Definitions
Equipment Devices PM-ICD-CRT-ILR
Devices interrogation Telemetry to retrieve information
Device programming Bidirectional telemetry
Programmer Receive and transmit info via telemetry
HM Remote device able to communicate with CIED
RM Remote wireless communication systems
Remote FU Remote FU Programmable scheduled transmissions
RM Automatically unscheduled transmissions
Pt initiated interrogations Non-scheduled FU as a result of a patient experiencing a real or perceived clinical event
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Table 2 Comparison of different remote monitoring systems
Biotronik Home MonitoringTM Medtronic CareLinkTM Boston Scientific
LatitudeTM
Sorin SMARTVIEWTM St Jude Merlin.netTM
Wireless communication
with implanted device
Radiofrequency Radiofrequency Radiofrequency Radiofrequency Radiofrequency
Data transmission GSM network Analogue phoneline and GSM
network
Analogue phoneline Analogue or GSM Analogue or GSM
Transmitter Mobile or stationary (GSM) Stationary Stationary Stationary Stationary
Frequency of
transmissions
Scheduled FU; daily FU; alert events Scheduled FU; alert events; on
patient demand
Scheduled FU; alert events Scheduled FU; alert events Scheduled FU; alert events
Remote follow-up Yes Yes Yes Yes Yes
RM Yes Yes Yes Yes Yes
Physician notification SMS, email, fax SMS, email Fax, phone Fax, email, SMS Fax, email, SMS
Feedback to patient via
transmitter




Automatic text and audio
messages




30 s (monthly periodic EGMs) 10 s 10 s 7 s 30 s
IEGM (arrhythmic
episodes)
All memorized episodes All memorized episodes All memorized episodes All memorized episodes All memorized episodes
FDA and CE Mark system
approval
Yes Yes Yes No Yes
Special features Automatic RV and LV thresholds. send
phone calls to pts
Automatic RA, RV, and LV
(Consulta and Protecta XT)
pacing thresholds
Optional wireless weight
scales and BP cuffs
Patient initiated transmissions Alerts fully configurable online
Comprehensive heart failure monitor,
intrathroracic impedance
measurement (CE-Mark only)
Optivolw lung fluid status alert Configurable data
transmission to
associated caregivers
SMARTVIEW HF featuring PhD
clinical status
Send phone calls to pats.
CoRVUE fluid status alert
Configurable red and yellow alerts Configurable red and yellow
alerts
Configurable red and yellow
alerts
PDF export of patient reports Automatic RA, RV, and LV pacing
thresholds (next generation of
ICDs)
Alerts fully configurable online. Patient
callback
ILR RM Electronic health record
data export capability
Access for heart failure
specialists and general
cardiologist.
Electronic health record export
compatibility
PDF export of patient reports
Devices available for RM Any already implanted devices
available for RM
RA, right atrial; RV, right ventricular; LV, left ventricular; IEGM, intracardiac electrogram; BP, blood pressure; GSM, global system for mobile communications.
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Remote follow-up
Refers to programmable scheduled transmissions in which routine
CIED parameters are collected remotely in a format similar to that
obtained during a routine clinic visit. This information obtained by
the caregiver from the data repository (usually via the internet) is
encoded in such a way that could be interfaced with commercially
available PMs and ICD follow-up software (i.e. Paceart). As
opposed to TTM, practically all information available through the
face-to-face interrogation with a programmer can be obtained.
Remote monitoring
Refers to data acquired automatically with unscheduled trans-
missions of any pre-specified alerts related to device functioning
or to clinical events. The latter adds a new functionality to
implanted devices, opening a new era of potentially beneficial
preemptive interventions that may alter the natural history of a
particular disease or condition.
Patient-initiated interrogations
Refers to non-scheduled follow-up interrogations as a result of a
patient experiencing a real or perceived clinical event, for which
the patient is seeking expert evaluation.
Description of the technology
Remote telemetry data are transmitted from the device to the
home monitoring (HM) station either by a ‘wand’ [remote trans-
mitter monitor (RTM)],14–16 or by wireless communication
between device and HM station. In addition to scheduled,
planned interrogation and data transmission sessions, automatic,
or alert-triggered data, [e.g. significant change in lead impedance,
development of persistent AF with fast ventricular rate close to
ventricular fibrillation (VF) zone, frequent episodes of ventricular
tachycardia (VT), delivery of (the device does not know
that shocks were inappropriate!) frequent shocks, or changes in
haemodynamic status] can be transmitted depending on the
device.17,18
This home monitor is linked by telephone to a central (internet-
based) secure server/secure website automatically to deposit the
data for further analysis. Transmission can also occur via an analogue
phone landline, a digital subscriber line, oradevice accessoryphone line.
The physician can receive a company alert notification via pager,
fax, SMS, voice message, or email. Many systems require access to a
dedicated (device- or company-specific) website to obtain detailed
information on the interrogation. The physician can activate either
manually or automatically message calls to patients to remind them
of upcoming remote follow-up appointments, to notify them if
they miss a remote follow-up appointment, to ask to call the
clinic, to inform that their remote transmissions have been
reviewed by the clinic, etc.19,20 Reprogramming of CIED by RTM
is not yet implemented in clinical practice, mainly due to safety
considerations regarding data protection and unauthorized
control of device function (Figure 2).
Review of existing evidence for
device-based monitoring focused
on insertable cardiac monitors
Arrhythmia (especially AF) and syncope are two important con-
ditions that should be optimally managed.21,22 In the case of AF,
it is the fact that many recurrences of AF do not lead to symptoms
but still represent a thread to the patient due to the risk of cer-
ebral and systemic embolism which not only applies to patients
on drug therapy but also to those after catheter ablation. The
detection of asymptomatic AF influences further treatment strat-
egies especially with regard to anticoagulation.23
Both patients with AF and those with syncope have to be mon-
itored. The effectiveness of monitoring in detecting events
depends on its continuity and duration.23– 25
Optimal monitoring requires patients’ acceptance, efficacy, sim-
plicity of application, and cost-effectiveness.
An important progress in this field at the end of the 20th
century was the introduction of systems that monitor the ECG
with tele-transmission of data [tele-event monitor with looping
memory, and mobile cardiac outpatient telemetry (MCOT)].
Such systems make it possible to assess parameters studied
almost immediately without a patient having to visit a medical
centre. Tele-event Holters are limited to diagnosing symptomatic
events since it needs to be activated by the patient who decides
when and whether the recording should be initiated and data
transmitted. Owing to the system of automatic analysis, MCOT
enables both asymptomatic events and those reported by patients
to be diagnosed. The adverse effects and the lack of acceptance by
patients limit the duration of monitoring to a few weeks at most.
Besides, it is difficult to make such monitoring continuously.26,27
This can be avoided by the use of ILRs, which have recently been
called insertable cardiac monitors (ICMs). They are small devices,
without any electrodes, which are implanted subcutaneously. Such
features of these devices secure full comfort of an examination.
Most of the ICMs evaluated so far require visits to a hospital to
have the recording analysed. Since 2010, different devices have
become clinically available. Current devices allow monitoring up
to 3 years, to register at any time (during symptoms or when
the patient or physician wishes so), to register automatically inci-
dents of asystole, bradycardia, ventricular and supraventricular
tachycardia or AF, and finally, to transmit data to the tele-centre
when the patient or the physician wishes so.
Although the implantation of the device is a small procedure and
does not last longer than 20 min, it is not without complications
(especially wound infections). Despite these potential compli-
cations inherent to any invasive procedure, an early use of ICMs
appears to facilitate diagnosis of syncope patients.28
The Tele-ICM system may also be useful being considered in
selected groups of AF patients, in diagnosing syncope, in selected
groups with signs and symptoms suggestive of arrhythmia, in risk stra-
tification in patients with depressed left ventricular function after
acute myocardial infarction, and in patients with genetically inherited
cardiac diseases, although formal clinical evaluation of the usefulness
of ICM in most of these situations is lacking at present.29




















Figure 2 Different systems available for remote monitoring. Images reproduced with permission of the suppliers.





















ICMs, like some PMs, have the capability to detect asymptomatic
AF adequately, and with markedly higher sensitivity than intermit-
tent electrocardiogram (ECG) monitoring techniques.24 –26,30
This has potentially relevant implications for the adequate diagno-
sis of AF, e.g. in survivors of a stroke or a transient ischaemic attack.
Some preliminary data suggest that a high burden of AF may have
implications for the likelihood of complications in AF patients, and
ICMs are capable of measuring AF burden.31 ICM could help to
assess the following questions: Whether anticoagulation therapy
may be discontinued,32,33 to develop criteria of effectiveness of AF
treatment, and to assess the real success rate of various therapies.
AF treatment has increasingly involved catheter-based ablation,
and a premium is placed on the accurate assessment of response
for the determination of ablation results and patient care. Misclassi-
fication of a patient’s response to the procedure can lead to serious
errors in management, especially with regard to stroke prevention. It
may be that an implantable loop recording system will provide the
greatest degree of compliance, accuracy (sensitivity95% and speci-
ficity 85%), and longevity for AF monitoring post-ablation,29
especially if systems can incorporate wireless and automated transfer
of data (rather than device interrogation in an office).34
The clinical value of ICM after the diagnosis of AF has been
established is relatively accepted in controlled trials, but is less
obvious for routine clinical practice.
Syncope
In 2009, the ESC in collaboration with EHRA, the Heart Failure
Association of ESC and the HRS released new guidelines on the
diagnosis and management of syncope.22 They differ from the pre-
vious ones in that they lay emphasis on the increasing role of a
diagnostic strategy based on prolonged monitoring (Class 1 indi-
cation for an early usage in the diagnostic work-up).34,35
Risk stratification in patients with
depressed left ventricular function after
acute myocardial infarction
Relatively common asymptomatic atrio-ventricular conduction dis-
turbances, accompanied by impaired left ventricular contractile func-
tion, significantly increase the risk for sudden cardiac death. The
experience from the CARISMA (Cardiac Arrhythmias and Risk Strati-
fication after Acute Myocardial Infarction) study36 confirms the effec-
tiveness of ILR in long-term assessment and ECG monitoring, providing
that this group of patients should undergo further clinical evaluation.
Risk stratification in genetically inherited
cardiac diseases
Clinical observations suggest that prolonged ECG monitoring with
the use of Tele-ICM could be applied in patients with such genetically
conditioned diseases as Brugada syndrome, long QT syndrome or
short QT syndrome, hypertrophic cardiomyopathy, or arrhythmo-
genic right ventricular cardiomyopathy. At present, Tele-ICM
offers a chance to take reasonable decisions on further treatment
especially in young people with asymptomatic congenital arrhythmo-
genic syndromes without documented dangerous arrhythmia.
Review of existing literature
for telemonitoring of devices
There are several papers supporting this technique, their useful-
ness, and benefits.
Lazarus16 and colleagues observed at the AWARE trial that the
application of a monitoring system strongly supports its capability to
improve the care of cardiac device recipients, enhance their safety,
and to optimize the allocation of health resources. He evaluated
3 004 763 transmissions made by 11 624 recipients of PMs (n ¼
4631), defibrillators (ICDs; n ¼ 6548), and CRT-D systems (n ¼
445) worldwide. The duration of monitoring/patient ranged from 1
to 49 months, representing 10.057 years. The vast majority (86%) of
events were disease related. The mean interval between the last
follow-up and the occurrence of events notified by HM was 26
days, representing a putative temporal gain of 154 and 64 days in
patients usually followed up at 6- and 3-month intervals, respectively.
Lead dysfunctions in ICD patients can lead to inappropriate
shocks and Spencker et al.37 evaluated how HM systems help phys-
icians to react quickly on these serious ICD malfunctions. He eval-
uated 54 patients who had to undergo resurgery due to
malfunctions of the ICD lead. Eleven of them were on HM inter-
rogating the device on a daily basis. The rate of inappropriate
shocks and symptomatic PM inhibition due to oversensing was
compared with the 43 patients without remote surveillance.
Home monitoring sent alert messages in 91% of all incidents.
Eighty per cent of the patients were asymptomatic at the first
onset of oversensing. Compared with the patients without HM,
inappropriate shocks occurred in 27.3% in the HM group vs.
46.5% (P ¼ n.s.). Event messages were dispatched in a mean of
54 days after the last ICD interrogation and 56 days before the
next scheduled visit. Thus, 56 days of reaction time are gained to
avoid adverse events. The authors conclude that the diagnosis
could be established correctly by an alert of the HM system, and
it might have a potential to avoid inappropriate shocks due to
lead failure and T-wave oversensing.37
Heidbuchel et al.38 analysed the significant burden on specialized
electrophysiology clinics which the follow-up of ICDs poses due to
the increased number of device implantations with regular in-office
visits every 3–6 months.
They evaluated 1739 prospectively coded ICD visits in a random
set of 169 patients. The standard follow-up scheme consisted of
in-office visits 1 month after implantation and then every 6
months, unless approaching battery depletion. The proportion of
relevant findings during unscheduled visits was significantly higher
than during scheduled visits (80.6 vs. 21.8%; P, 0.0001) and a
higher proportion of those was arrhythmia- and/or device-related
(85.1 vs. 55.3%; P, 0.0001). Reprogramming was required more
often (33.1 vs. 4%; P, 0.0001) and hospitalization rate was higher
(18.3 vs. 2%; P, 0.0001), so that 51.4% of unscheduled visits
would require in-office evaluation. Overall, remote follow-ups
would correctly exclude device function abnormalities or arrhyth-
mic problems in 1402 (82.2%) cases, identify an arrhythmic
problem in 262 (15.3%), and correctly identify a device-related
problem in 35 (2.1%). Clinical evaluation would diagnose a relevant
clinical problem without any device interrogation abnormality in 170




















patients (10%). They conclude that ICD RM can potentially diagnose
.99.5% of arrhythmia- or device-related problems if combined with
a follow-up by the local general practitioner and/or referring cardi-
ologist. Its use may provide a way to significantly reduce in-office
follow-up visits that are a burden for both hospitals and patients.
A similar study was performed by Elsner et al.39 [REFORM]. They
investigated in a prospective, randomized, and multicentre compari-
son study the effect of ICD HM against conventional follow-up (FU)
in 115 MADIT II patients. The results prove that the simplified ICD
follow-up scheme with additional HM in MADIT II patients can
reduce the number of visits and lead to time reduction.
In a very interesting review, Schmidt et al.40 evaluated how tele-
monitoring can improve the medical care, quality of life, and prog-
nosis on patients with chronic congestive heart failure. They
searched the Medline database for articles appearing from June
2001 to May 2008, with an emphasis on randomized, controlled
trials. Their data suggested that telemonitoring is effective, yet
there is no evidence for superior outcomes with any particular
model of care incorporating telemonitoring (i.e. monitoring of
vital signs vs. structured telephone monitoring).
The PREFER study10 was a prospective, randomized, parallel,
unblinded, multicentre trial to determine the utility of remote
PM interrogation for the earlier diagnosis of clinical events com-
pared with the existing practice of TTM and routine office visits.
There were 866 clinical events reported in 382 patients in the
study. The number of events reported per patient was 0.517 in
the remote arm and 0.308 in the TTM, and the most frequent
was non-sustained VT, followed by atrial tachycardia/AF episodes
lasting 48 h or longer. The authors conclude that the use of
remote PM interrogation follow-up detects clinically important
events that require action more quickly and frequently than trans-
telephonic rhythm strip recordings. Similar results were observed
at the CONNECT study.41
Jung et al.5 published data collected in several completed and
ongoing studies which results strongly suggest that this new technol-
ogy will make important contributions, particularly with respect to
the facilitation of ICD follow-ups, enhancement of patient safety,
and quality of life. The life-saving potential of automatic daily RM
messages has been illustrated by reports of lead failures and
device dysfunctions: Neuzil et al.42 described the failure of an ICD
to properly charge its capacitors and deliver appropriate therapy.
Spencker et al.43 observed a fall in atrial pacing impedance from
daily remote messages. Ritter and Bauer44 reported two cases of
inappropriate VT detection caused by supraventricular tachycardia
and intermittent T-wave oversensing, respectively, both diagnosed
on the basis of remote transmissions of intracardiac electrogram,
and immediately managed at the time of non-routine follow-ups.
These cases, observed during the early years of HM, will likely
increase in numbers as its clinical applications increase.
Indications
Diagnosis of symptomatic and
asymptomatic events
Electronic cardiovascular implantable devices collect, quantify, and
analyse important information regarding their own function and
patient conditions. These data are conventionally accessed by phys-
ically downloading stored diagnostic information. Monitoring guide-
lines recommend a follow-up method based on frequent in-person
scheduled evaluations.4 This ignores problems occurring between
calendar-based scheduled appointments in the majority of the
time. Remote monitoring may solve this problem; however, technol-
ogies differ in application. Earlier systems demanded patient-
activated transmissions on a calendar basis. Short, small-scale feasi-
bility studies demonstrated ability to detect asymptomatic lead and
generator problems e.g. T-wave oversensing, battery elective repla-
cement indicators (ERI).8,17 When used to follow up a PM popu-
lation, only 66% of data were transmitted and clinical events
requiring action were detected several months later.10
Automatic RM, in contrast, promises the maintenance of near-
continuous surveillance independent of schedule or patient or
physician interaction. Home monitoring self-tests system perform-
ance daily and employs automatic device-triggered transmissions
for rapid problem notification regardless of interrogation sche-
dules.45 These may concern arrhythmias, device activities, or
acute deviations from established trends (e.g. AF, VF, ERI, impe-
dances out of range).45,46 Events may be transmitted immediately
and flagged for attention irrespective of associated symptoms.
This is especially important for potentially dangerous silent events.
Automatic RM was prospectively tested and compared with
conventional in-person follow-up in the Lumos-T Safely
RedUceS Routine Office Device Follow-up (TRUST) multicentre
trial.47,48 Early detection was assessed by time elapsed from
event onset to physician evaluation. In conventional care, this
occurred at in-office interrogation (scheduled or unscheduled).
Evaluation in HM occurred on receipt of event notifications in
response to detection of pre-programmed events or in-office
interrogation (scheduled or unscheduled). Investigators recorded
whether these events were clinically asymptomatic (‘silent’).
TRUST results demonstrated that HM enhanced problem discov-
ery of clinically silent as well as symptomatic events, despite less
frequent hospital evaluations.48 Detection was advanced by more
than 30 days compared with conventional care and this advantage
would be greater if conventional visits were scheduled 6 or 12
monthly. Arrhythmias were the most common cause for event
notifications. Median time from onset to physician evaluation of
combined first AF, VT, and VF events in HM was 1 day, signifi-
cantly less than the value in conventional care of 35.5 days
(Figure 3).
System-related problems occurred infrequently but were often
asymptomatic. Conventional follow-up resulted in delayed detec-
tion and underreporting of important events.48 In contrast, HM
enabled prompt detection (,24 h). Event triggers covered an
extensive range of potentially lethal (and asymptomatic) system
problems, e.g. ERI, lead fracture, high-voltage circuitry failure, and
permit prompt intervention either surgically, e.g. for lead
failure,49–51 or conservatively, e.g. to prevent potential inappropri-
ate therapies (e.g. electromagnetic interference, AF). The non-
sustained ventricular arrhythmia notification may be triggered by
system issues such as lead electrical noise artefacts caused by frac-
ture or non-physiological electrical signals. Identification of patients
with a high burden of these may facilitate intervention to preempt
premature battery depletion.52 Notification for disabled VF




















detection is important as more patients with different comorbid-
ities undergo procedures in different departments.
These data illustrate that problems occurring in patients with
implanted devices are often clinically silent but may be revealed
by automatic RM technology. The ability to generate parameter
trends with high temporal resolution permits adjudication of
asymptomatic deviations from baseline values. Plots that are
updated frequently when coupled with ability for rapid notification
deviations may enable therapeutic intervention.53
Utility in certain pathologies: congestive
heart failure and atrial fibrillation
Heart failure
There are several methods currently available to identify patients
at risk of worsening heart failure (Table 3). Commercially available
methods include assessment of weight as well as intrathoracic
impedance. The feasibility of daily monitoring of weight (with the
physician alerted to a weight gain or loss of 2 pounds over 2
days or 5 pounds over a week) has recently been demonstrated
in a large clinical trial;54 however, long-term outcome data are
still needed. Intrathoracic impedance appears to be inversely cor-
related with pulmonary capillary wedge pressure and fluid balance;
it declines before the onset of patient symptoms and before hos-
pital admission for fluid overload.55,56 However, as a singular indi-
cator, it lacks adequate sensitivity and specificity to guide clinical
decision making. More recently, a system to measure left atrial
pressure directly has been reported;57 a large-scale trial to evaluate
the system clinically is currently underway.
Abraham et al.58 evaluated patients with New York Heart
Association (NYHA) Class III heart failure which were randomly
assigned by use of a wireless implantable haemodynamic monitor-
ing system or to a control group for at least 6 months. Eighty-three
heart-failure-related hospitalizations were reported in the treat-
ment group (n ¼ 270) compared with 120 in the control group
(n ¼ 280, P, 0.0001). During the entire follow-up, the treatment
group had a 39% reduction in heart-failure-related hospitalization
compared with the control group (153 vs. 253; P , 0.0001).
These results are consistent with, and extend, previous findings
by definitively showing a significant and large reduction in hospital-
ization for patients with NYHA Class III heart failure who were
managed with a wireless implantable haemodynamic monitoring
system.
Atrial fibrillation
Atrial fibrillation is the most commonly encountered arrhythmia in
clinical practice, is a major cause of ischaemic stroke, and can con-
tribute to the development of heart failure. For all these reasons,
confirming the diagnosis of AF is important in many patients, and
defining response to therapeutic interventions is crucial irrespec-
tive of treatment option. There are several reasons that establish-
ing the presence and quantity of AF has been challenging: AF can
have a multitude of symptoms, but none are specific for diagnosis
of this arrhythmia; many patients have asymptomatic AF episodes
even when the patient is known to suffer from symptomatic AF;
and therapeutic interventions (both drug and ablation) may alter
the perception of AF. Hence ECG confirmation is considered
the gold standard for AF detection. Historically, the 12-lead ECG
Table 3 Device parameters used to track the heart
failure patient
‘Vital signs’
† Weight and blood pressure (daily)
Symptoms
† Quality-of-life questions (weekly)
† Assessment of patient activity
Lead related
† Significant increase in pacing thresholds, especially the left
ventricular lead
† Significant increase in the percentage of right ventricular pacing






† Heart rate variability
† Respiratory rate
Figure 3 Home monitoring vs. conventional care (days): atrial
fibrillation: median, 5.5 vs. 40; interquartile range, 1–51.25 vs.
15.5–59; ventricular tachycardia: median, 1 vs. 28; interquartile
range, 1–6 vs. 6.5–69.25; ventricular fibrillation: median, 1 vs.
36; interquartile range, 1–7 vs. 10–75; sustained ventricular
tachycardia (SVT): median, 2 vs. 39; interquartile range, 1–19.5
vs. 8.5–69). Clinically asymptomatic(silent) problems were also
detected early in home monitoring for combined first atrial fibril-
lation, ventricular tachycardia, ventricular fibrillation, or SVT
events (median, 1 vs. 41.5; interquartile range, 1–6 vs. 10.5–
70.25). Compiled with permission from Varma et al.48




















and ambulatory monitoring were the common modes used for AF
recording, but these modalities are too brief to provide assurance
of detection of AF and its pattern or its absence.
Prolonged or permanent arrhythmia monitoring is generally
restricted to permanently installed devices including PMs, defibril-
lators, and resynchronization systems, provided that an atrial lead
has been implanted. Continuous atrial sensing and programmable
algorithms that detect elevated atrial rates are the primary
means by which atrial tachyarrhythmias can be captured and quan-
tified with high sensitivity and good specificity. It is important to
recognize that a detected atrial high rate event (AHRE) is not
synonymous with AF and is sensitive to the programmed rate
cutoff and duration, and is further limited because only a single
atrial site is sampled. There may also be oversensing on the
atrial channel and thus diminished specificity. Acquired data can
be interrogated in a clinic or obtained through RM and can
include the atrial rate and regularity, associated ventricular rate,
electrographic confirmation, duration of episode(s), and frequency
of episodes. The latter two may be utilized to calculate what is
commonly referred to as ‘AF burden’. One study demonstrated
the utility of newly implanted PMs for the initial diagnosis of AF
with an incidence of about 25% over 1 year.59
The clinical significance of AHREs is still being debated. In a pro-
vocative analysis, the MOST investigators concluded that the pres-
ence of ≥1 AHRE of ≥ 5 min at 1 year was associated with a
slightly higher mortality rate although not a higher stroke rate.60
These brief PM-detected events may simply be a marker of older
age, more advanced cardiovascular disease, and prior AF. Indeed,
the duration of AF detection from implanted PMs has been corre-
lated to the risk of stroke, greatest when AF exceeded 24 h, with
risk further modulated by conventional criteria.33
The threshold at which AHRE detection should trigger interven-
tion including anticoagulation in higher-risk patients has not been
defined. In a recent investigation,61 only a borderline increased risk
of stroke was calculated in a convoluted secondary analysis when
the AHRE burden exceeded 5.5 h compared with no or shorter dur-
ation AHRE, but the overall event rate was so low that the primary
endpoint comparisons could not be performed. Several important
questions still need to be addressed including whether any single
episode longer that a prespecified duration is critical, or whether
the overall burden of arrhythmia is more important.
As contemporary devices also have the capability of RM and
physician notification based on prescribed criteria, they can serve
as early-warning systems should an arrhythmic event be
detected.18 In the TRUST study,48 the time to physician evaluation
for a detected AF event was reduced from 40 to 6 days. Whether
this leads to a favourable clinical outcome was not tested. This
technology, however, could be exploited to allow targeted anti-
coagulation (or antiarrhythmic therapy) if and when AF is detected
in an early phase (e.g. at 12–48 h after onset), and even anticoagu-
lation withdrawal when AF has subsided. Devices could be pro-
grammed to alert the patient directly or could be monitored and
verified by a centralized service provider. This unproven, but tan-
talizing, tailored approach is being tested in a randomized clinical
trial vs. standard care.62 The recent availability of the rapidly
acting oral anticoagulant dabigatran (as opposed to warfarin)
makes this strategy particularly attractive. Hanke et al. evaluated
45 cardiac surgical patients treated with either left atrial epicardial
high-intensity focus ultrasound ablation (n ¼ 33) or endocardial
cryothermy (n ¼ 12) in the case of concomitant mitral valve
surgery.63 Sinus rhythm was documented in 53 readings of 24
Holter Monitoring, in 34 of these instances by the implantable con-
tinuous cardiac rhythm monitoring in the time period before
24HM readings (64%; P, 0.0001), reflecting a 24HM sensitivity
of 0.60 and a negative predictive value of 0.64 for detecting AF
recurrence. The authors concluded that continuous heart
rhythm surveillance instead of any conventional 24HM follow-up
strategy is necessary in this group of patients.
Benefits of remote monitoring
There are many potential benefits of remote patient monitoring
(RPM) for the patient and their caregivers, the follow-up centres,
the health care infrastructure, the manufacturer, and the discipline
of cardiac implantable electronic device (CIEDs) management.4
Several recent studies [COMPAS, CONNECT, OEDIPE,
PREFER, REFORM, and TRUST10,13,39,41,48,64,65 in addition to
important registry data (ALTITUDE13)] today constitute a strong
evidence base for RM. In the very early days of RM, there was
concern expressed, as there is with most new technologies, that
patients and caregivers would not be satisfied with RM because
they would lose the advantage of a face-to-face visit, despite the
fact that scheduled, routine follow-up visits have in practice a
very low actionability rate.48 Today multiple studies have shown
that both patients and caregivers are satisfied with RM both in
terms of its ease of use and continued connectedness to the
follow-up centre.66
In addition, RM is adding strong benefits to the patient’s peace of
mind, psychological well-being, and safety specifically following an
advisory and therefore is seen as an important alternative to the
current standard of care.43,67– 69
In addition, patients require fewer overall visits to the follow-up
clinic when RM is employed. Both very large trials, the
CONNECT41 and TRUST,48 demonstrated a significant cut in
the total number of in-office visits (3.92 in RM and 6.27 in-office
in CONNECT and 2.1 in RM and 3.8 in-office in TRUST).
Further trials and real-life studies showed a cut in in-office visits
by up to 63%.39,70 This significant reduction contributes to the
effectiveness of the health care system as the workload for care-
givers in the device clinic is reduced by RM.39 In the study by Raa-
tikainen et al.71 physicians and nurses’ time required for an office
visit vs. a follow-up by RM was assessed. The physician time
required to review the RM data (8.4+ 4.5 min, range 2–30 min)
was significantly shorter than the time needed to complete a
device follow-up visit in the clinic (25.8+ 17.0 min, range 5–
90 min), P, 0.001. Likewise, allied professionals spent more
time on an in-clinic visit when compared with an RM follow-up
assessment (45.3+ 30.6 vs. 9.3+15.9 min; P, 0.001).
The significant higher adherence rate of RM vs Control (RM
92.7% vs. Control 89.2%, P, 0.001) may be explained by the
lower burden for the patient, the caregivers, and the dramatically
higher actionability rate of an RM-triggered follow-up compared
with a scheduled follow-up visit.48




















Remote monitoring provides timely
detection of clinical events
Another important benefit is that RM detects clinical abnormalities
that would be either completely missed by less frequent in-office
visits, or detected significantly later in the absence of close to con-
tinuous RM data assessment. Clinical data demonstrate earlier
detection of clinical events of up to 148 days.10,37,41,48,61 The
TRUST trial48 reports that median time from onset to physician
evaluation of combined first AF, VT, and VF events was significantly
reduced from 35.5 days to only 1 day in the remote follow-up arm.
Furthermore, even though very rare, problems with pulse genera-
tors and leads were detected significantly earlier (RM 4.4+ 9.2
days vs. Control 23.6+ 40.2 days)48 Overall, the study detected
20 device-related problems that required surgical revision; 15 of
these were detected by RM and only 5 in their control group.
The CONNECT trial41 reports that the time from a clinically
significant event to making a clinical decision in the RM arm
was 4.6 days in the remote arm vs. 22 days in the in office
arm—significantly shorter. Perhaps as a result of earlier detection
of clinical problems, resulting hospitalizations may be shorter in
those patients on RM. In the CONNECT trial,41 the RM arm of
the trial had significantly shorter hospitalization length of stay
than those patients followed in the clinic (3.3 vs. 4.0 days; P ¼
0.002). A broad benefit of RM is the ability to obtain clinically
useful data from very large-scale registries offering an insight into
real-world outcomes. For example, observational data of the
large-scale ALTITUDE study13 demonstrated at 1 and 5 years
higher survival rates for ICD/CRT-D patients on RM vs. the stan-
dard of care group (50% reduction, P, 0.0001). However, the
lack of clinical profile data and specific knowledge of comorbid
conditions in this registry limits interpretation and assignation of
clinical significance to this novel observation and supports future
studies aimed at confirming this observation. Other observational
studies demonstrated improved clinical management of patients
with CIED.18 There is a clear need to assess whether earlier detec-
tion of events results in better management and outcome of
patients on RM, or whether earlier detection of events increases
health care utilization to an extent that offsets these potential
benefits.
Legal considerations
The rapid evolution and growing use of RM will likely present new
legal challenges. The transmission, storage, sharing, and interpret-
ation of CIED diagnostics each will fall under scrutiny to assure
that patients’ and health care providers’ rights are maximally pro-
tected. In the USA, the Health Insurance Portability and Account-
ability Act (HIPAA) of 1996, the Health Information Technology
for Economic and Clinical Health Act, and Code of Federal Regu-
lations provide a general framework addressing the security and
privacy of Protected Health Information. Health care providers
and health care organizations that are involved in RM of CIEDs
will typically sign a ‘Terms of Use’ agreement and when applicable
a ‘Business Associate Agreement’ with each of the CIED vendors.
These legal documents outline the provisions of RM between the
CIED vendor and the user.
The patient needs to be informed of the purpose and limitations
of RM, such as the fact that it does not replace an emergency
service or absence of dealing with alert events outside office
hours. Before initiating RM and follow-up, the patient may be
requested to sign a written informed consent stating these
points and authorizing transmission of personal data to third
parties, respect of privacy, and confidentiality of patient data by
device companies should be subjected to strict rules, described
in contracts.
Vulnerability of security breaches by hackers accessing devices
with wireless capability must be tested in every system. Halperin
et al.72 performed laboratory tests using several software radio-
based attacks that were able to retrieve encrypted personal
patient data, as well as to reprogram device settings (including
commanded shocks). This report triggered considerable media
coverage, although it is believed that the risk of unauthorized
access to an ICD is unlikely, given the considerable technical
expertise required.73 There have been no reports to date of
unauthorized reprogramming of implantable devices; however,
unauthorized access to personal information stored on internet
servers must be also considered.
Cardiac implantable devices record a wealth of information and
as devices become more sophisticated the scope of information
can be expected to grow. Current CIEDs provide not only
arrhythmia information but also several indicators of heart failure.
Cardiac implantable device transmissions may occur either over
telephone lines or over cellular network lines. These transmissions
often only take less than a minute to a few minutes to complete.
However, in the foreseeable future we can expect alternative
methods of data transmission to become available with trans-
mission rates that will make it possible for nearly continuous and
instantaneous patient CIED data delivered to health care providers.
There are, of course, limitations to how frequently CIED data can
be reviewed by health care providers and battery longevity con-
straints will likely limit the transmission times as well. If for
example, an ICD lead alert suggestive of an impending lead
failure becomes available on a Saturday at midnight, what would
be considered a ‘reasonable’ response time to this alert? What if
that night the same patient developed ventricular fibrillation and
ICD therapies failed, what would have been a ‘reasonable’
response time then? Institutional guidelines and/or caregiver and
patient contracts may need to be devised so as to limit the
periods of liability. In addition, guidelines may need to be estab-
lished to determine the periodicity with which CIED transmissions
would need to be reviewed and documented.
The growing number of patients with CIEDs and the accumulat-
ing data may lend itself to vital analyses and may yield significant
prognostic information. However, access to these data is another
area that will require legal inquiry. Who should be the custodian
of these data, if anyone? Who should be able to access these
data, if anyone? What may be the effect of any results on a class
of patients?
Technological advancements continue to structure our practice
of medicine, but with it often new legal challenges emerge. In order
to minimize risk to patient and liability to health care providers a
clear discussion regarding the expectations and limitations of RM
between patients and health care providers is recommended.





















Despite the value of CIEDs today, there remains considerable need
for follow-up-therapy improvement to maximize patients’ health
and safety. Continuous patient and device RM and the replacement
of often ineffective48 but resource intensive calendar-based follow-
ups4,5 would contribute strongly to the effective prevention, detec-
tion, and sufficient management of medical or technical events. The
significant limitations of today’s in-office follow-up such as late
detection of medical or technical events with potentially serious
health outcome implications and the high resource intensity of
calendar-based follow-up often leading to adherence challenges
have been described in more detail elsewhere.6,10,41,74,75 Remote
monitoring has been developed to address these limitations by
offering need-based and continuous surveillance of the devices
and patients to improve safety and cost-effective delivery of
health care.
Today, physician reimbursement remains a major concern with a
lack of appropriate reimbursement in place in most countries
worldwide and as a result limiting an increased use of evidence-
based RM.
Today’s cost containment pressure requires increased reimbur-
sement efforts with the burden of proof shifting to medical com-
munities and manufacturers. Reimbursement assessments often
begin with the presumption that a technology or service will not
be covered unless its use is supported by scientific evidence of
improved outcomes.74 Whereas it is generally out of question
that physicians need to be adequately paid for their services, the
current discussions around physician reimbursement is focused
on the questions whether RM is safe, effective, and cost-
effective.76– 78 However, existing health technology assessments
are at least partially obsolete as they could not take the only
recently available Level 1 evidence into consideration at the time
of their review74– 76,79 (Table 4).
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Table 4 Reimbursement for remote monitoring of cardiac devices
Country/region None Hardware and industry service reimbursement Physician reimbursement







Asia-Pacific / Australia X
Baltic states X
Belgium x





France X (BIOTRONIK and Boston Scientific only) x




Japan x X (with restrictions)









The table presents the current reimbursement status for RM of CIEDs. Three reimbursement categories can be differentiated. Reimbursement needs to be established for the
time spent by the physician to assess the information (Category 3). In addition, reimbursement tariffs need to be established for the transmitting hardware and the transmission
costs such as telephone costs (Ccategory 2) as well as for the RF-enabling CIEDs (category).
Reimbursement categories
1. Countries with higher reimbursement for selected RF-enabled implantable devices.
2. Countries with reimbursement for patient monitors or with approved reimbursement codes for remote follow-up or implanted cardiac devices for doctors/clinics.
3. Countries where existing codes for in-office follow-up are being used to reimburse for remote follow-up for doctors/clinics.
From Eucomed (CRM Telemonitoring Working Group). Business development (2009).




















In 2010/11, on top of observational data of more than 20 000
patients, the scientific evidence base for RM has significantly
changed with the publication of the results of five RCTs with
altogether more than 4000 patients.10,20,29,39,41,48,65,71
A strong safety profile, the effectiveness, and a positive impact
on resource utilizations in comparison with calendar-based
in-office follow-up visits has been consistently and repeatedly
demonstrated.32,34,36,37,41
The vast majority of ICD recipients have some degree of left
ventricular systolic dysfunction and these patients are at risk of
heart failure hospitalizations, which impose a major economic
burden on the health care system. So concerned were the
Centers for Medicare and Medicaid Services about the adverse
economic implications in the USA of recurrent heart failure hospi-
talizations that, in January 2009, they afforded favourable financial
reimbursement to physicians who chose to manage device patients
remotely. Specifically, monthly reimbursement is available for RM
of an ‘implantable cardiovascular monitor system’; the latter,
which can be either a stand-alone device or incorporated into a
PM or ICD system, provides physiologic cardiovascular data
elements from internal (transthoracic impedance, heart rate varia-
bility, respiratory rate, intracardiac pressures), and external (weight
and blood pressure) sensors. A recent meta-analysis suggests a
reduction in hospitalizations and death in heart failure patients
monitored remotely as compared with usual care.79
A recent meta-analysis by Klersy et al.80 showed that manage-
ment of heart failure patients by RM is cost-saving due to a sub-
stantial reduction in health care resource utilization mostly
driven by a reduction in the number of HF hospitalizations. The
cost saving expected in both European and US health care
systems is linearly related to the implementation rate of RPM.
An important caveat is the limited follow-up time of the studies
considered in this meta-analysis, which restricted the time
horizon for the cost-effectiveness assessment to 1 year. The
novel cost-effectiveness data coupled with the demonstrated clini-
cal efficacy of RPM should encourage its acceptance among clini-
cians and its consideration by third-party payers. At the same
time, the scientific community should acknowledge the lack of pro-
spectively and uniformly collected economic data and should
request that future studies incorporate economic analyses.
However, one should recognize that most of the cost-effectiveness
data analyses are frequently considering relatively outdated tech-
nologies or management disease programmes, which have not
included implantable device based; thus, extrapolation to device-
based telemonitoring should be done cautiously.81
With this supportive evidence in place the responsibility for
establishing reimbursement policies is now shifting back to the
policy makers. Today’s evidence demonstrates that a replacement
of calendar-based follow-ups with RM can increase patient safety
by early detection of technical events, reduce the number of
in-office follow-ups, detect medical events early, may reduce
length of stay and hospitalization rates, may reduce the risk of
stroke and atrial arrhythmias, and may cut down mortality risk
by about 50%.7,10,13,41,48,60,66,76
The lack of appropriate reimbursement led to a relative paucity
of real-life outcomes research data. Therefore, some, however,
manageable real-life performance uncertainty of RM may remain.
Reimbursement policies for RM of CIEDs services and hardware
need to be enforced in a timely manner to remove a remaining
barrier for a more widespread use of evidence-based RM of
CIEDs to significantly improve post-implant patient management.
Innovative reimbursement schemes such as coverage with evi-
dence in development60 might be a viable option to overcome
the current discrimination of RM reimbursement. Based on
today’s convincing evidence in place the utilization of RM should
not be further limited by discriminative reimbursement policies
but should be left to the decision making of doctors and patients
to optimize individual patient care.
Final comments
Telemedicine is a rapidly growing area where technological develop-
ments currently far exceed clinical experience and evidence-based
strategies. Remote monitoring of CIEDs represents a growing
market with increasing numbers of patients being subject to these
technologies but also more and more physicians are involved in
decision making on the indications for these technologies and the
handling of data in the context of clinical decision making.
As device technology is fast moving and the operational mode
for performing telemonitoring is rapidly evolving, it is important
to consider that novel operational platforms for in- and
out-of-hospital patient management are highly needed, new edu-
cation and competence definition of allied professionals are
needed, and urgently require attention from scientific societies.
Finally, given the significant economical burden that telemedicine
may pose on an already very fragile and underfinanced health
care system, it is imperative to find the appropriate timing cycle
for economical evaluation of novel technologies and for fast
update of health technology assessment.
Two international organizations agreed upon this consensus state-
ment which has assembled the currently available information on
systems and on results of their use under various clinical conditions.
Future research in this area will need to concentrate on several
issues of which a few will be mentioned here:
(1) What is the sensitivity and specificity of data obtained from
CIEDs under various specific clinical conditions?
(2) What is the time interval between CIED-based detection of an
abnormality and measures to be taken by the responsible
physician or the patient?
(3) While RM is intended to reduce the need for some
face-to-face scheduled clinic visits, what is its impact on
various outcome parameters such as quality-of-life, adverse
events, even on mortality, etc.?
(4) With increasing number of patients with CIEDs, what is the
impact on physician and technician working load?
(5) What is the cost-effectiveness ratio of such systems?
(6) What are potential, not yet identified problems with regard to
patient data protection, and what are the potential differences
of these problems with various national and international legal
systems (with data stored outside one’s own country)?
These and other questions will have to be answered by further
research in this area. If this is encouraged by this document, then




















a major aim has been reached besides presenting the currently
available knowledge and experience of the use of CIEDs.
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